Antiemetics of the 5-hydroxytryptamine 3A antagonist class inhibit muscle nicotinic acetylcholine receptors

Anesthesia and Analgesia

Volumn 101, Issue 3, 2005, Pages 715-721

  Paul, Matthias ^a   Callahan, Robert ^b   Au, John ^b   Kindler, Christoph H ^c   Yost, C Spencer ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; DOLASETRON MESILATE; DRUG METABOLITE; GRANISETRON; HYDRODOLASETRON; ION CHANNEL; LIGAND; NEUROMUSCULAR BLOCKING AGENT; NICOTINIC RECEPTOR; ONDANSETRON; RAPACURONIUM BROMIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 3A RECEPTOR; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VECURONIUM;

ANIMAL CELL; ARTICLE; CHANNEL GATING; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; IC 50; ION CURRENT; MAMMAL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; VOLTAGE CLAMP; XENOPUS LAEVIS;

EID: 23944459748     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000160531.65953.77     Document Type: Article

References (27)

1. Habib AS, Gan TJ. Evidence-based management of postoperative nausea and vomiting: a review. Can J Anaesth 2004;51: 326-41.
2. Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 1995;15:1231-44.
3. Maricq AV, Peterson AS, Brake AJ, et al. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991;254:432-7.
4. Boess FG, Beroukhim R, Martin IL. Ultrastructure of the 5-hydroxytryptamine3 receptor. J Neurochem 1995;64:1401-5.
5. Colomo F, Rahamimoff R, Stefani E. An action of 5-hydroxytryptamine on the frog motor end-plate. Eur J Pharmacol 1968;3:272-4.
6. Grassi F, Polenzani L, Mileo AM, et al. Blockage of nicotinic acetylcholine receptors by 5-hydroxytryptamine. J Neurosci Res 1993;34:562-70.
7. Garcia-Colunga J, Miledi R. Effects of serotonergic agents on neuronal nicotinic acetylcholine receptors. Proc Natl Acad Sci USA 1995;92:2919-23.
8. Garcia-Colunga J, Miledi R. Serotonergic modulation of muscle acetylcholine receptors of different subunit composition. Proc Natl Acad Sci USA 1996;93:3990-4.
9. Neild TO. The action of 5-hydroxytryptamine and possible 5-hydroxytryptamine antagonists on neurones of the guinea-pig submucous plexus. Gen Pharmacol 1981;12:281-4.
10. Vanner S, Surprenant A. Effects of 5-HT3 receptor antagonists on 5-HT and nicotinic depolarizations in guinea-pig submucosal neurones. Br J Pharmacol 1990;99:840-4.
11. Mishina M, Takai T, Imoto K, et al. Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 1986;321:406-11.
12. Paul M, Kindler CH, Fokt RM, et al. The potency of new muscle relaxants on recombinant muscle-type acetylcholine receptors. Anesth Analg 2002;94:597-603.
13. Garcia-Colunga J, Miledi R. Blockage of mouse muscle nicotinic receptors by serotonergic compounds. J Exp Physiol 1999;84: 847-64.
14. Nakazawa K, Ohno Y. Block by 5-hydroxytryptamine and apomorphine of recombinant human neuronal nicotinic receptors. Eur J Pharmacol 1999;374:293-9.
15. Grassi F. 5-Hydroxytryptamine blocks the fetal more potently than the adult mouse muscle acetylcholine receptor. Pfluegers Arch 1999;437:903-9.
16. Information ZP. Research Triangle Park, NC: Glaxo Wellcome, 1999.
17. Information KP. Nutley, NJ: Roch Pharmaceuticals, 2000.
18. Kuryshev YA, Brown AM, Wang L, et al. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 2000; 295:614-20.
19. Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996;28:53-9.
20. Boike SC, Ilson B, Zariffa N, Jorkasky DK. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997;54: 1172-6.
21. Waud DR, Waud BE. In vitro measurement of margin of safety of neuromuscular transmission. Am J Physiol 1975;229:1632-4.
22. Dimmitt DC, Choo YS, Martin LA, et al. Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers. Part I. Biopharm Drug Dispos 1999;20: 29-39.
23. Grunberg SM, Groshen S, Robinson DC, et al. Correlation of anti-emetic efficacy and plasma levels of ondansetron. Eur J Cancer 1990;26:879-82.
24. Lien CA, Gadalla F, Kudlak TT, et al. The effect of ondansetron on atracurium-induced neuromuscular blockade. J Clin Anesth 1993;5:399-403.
25. Gyermek L. Is d-tubocurarine an antiemetic? Acta Anaesthesiol Sin 1996;34:53.
26. Yan D, Pedersen SE, White MM. Interaction of D-tubocurarine analogs with the 5HT3 receptor. Neuropharmacology 1998;37: 251-7.
27. Min KT, Wu CL, Yang J. Nondepolarizing neuromuscular blockers inhibit the serotonin-type 3A receptor expressed in Xenopus oocytes. Anesth Analg 2000;90:476-81.